Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syndax Pharmaceuticals

9.92
-0.0700-0.70%
Volume:1.99M
Turnover:19.67M
Market Cap:853.59M
PE:-2.57
High:10.04
Open:9.77
Low:9.57
Close:9.99
Loading ...

Syndax Pharmaceuticals Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
28 Jul

Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613

TIPRANKS
·
25 Jul

TD Cowen Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)

TIPRANKS
·
22 Jul

Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves!

TIPRANKS
·
19 Jul

Syndax Pharmaceuticals Inc. CEO Michael A. Metzger Reports Disposal of Common Shares

Reuters
·
19 Jul

CFO Keith A. Goldan Reports Disposal of Common Shares in Syndax Pharmaceuticals Inc

Reuters
·
19 Jul

UBS Adjusts Price Target on Syndax Pharmaceuticals Inc to $35 From $37, Maintains Buy Rating

MT Newswires Live
·
15 Jul

SNDX, NUVB, AURA : 3 Russell 2000 Stocks Analysts Say Could Soar Over 200%

TIPRANKS
·
11 Jul

Syndax Pharmaceuticals Initiated at Buy by Goldman Sachs

Dow Jones
·
10 Jul

Promising Growth Potential for Syndax Pharmaceuticals Driven by Revuforj and Strategic Partnerships

TIPRANKS
·
10 Jul

Syndax Pharmaceuticals Unveils New Inducement Plan, Grants Stock Options to 14 New Employees

Reuters
·
03 Jul

William Meury Resigns from Syndax Pharmaceuticals Board to Join Incyte Corporation as CEO

Reuters
·
26 Jun

Syndax Gets US FDA Priority Review of Supplemental New Drug Application for Revuforj in Acute Myeloid Leukemia

MT Newswires Live
·
25 Jun

Syndax Pharmaceuticals (SNDX) Receives a Buy from Barclays

TIPRANKS
·
16 Jun

Syndax Pharmaceuticals Announces Promising Results from BEAT AML Trial with Revumenib at EHA 2025, Highlighting Potential Cornerstone Therapy for Acute Leukemias

Reuters
·
13 Jun

Syndax announces new data from AUGMENT-101 trial of Revuforj

TIPRANKS
·
12 Jun

Syndax Pharmaceuticals Announces FDA Approval of Revuforj for R/R Acute Leukemia with KMT2A Translocation and Submits Supplemental NDA for R/R mNPM1 AML

Reuters
·
12 Jun

Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating

TIPRANKS
·
06 Jun

Syndax Pharmaceuticals Announces Inducement Awards for New Employees Under 2023 Plan

Reuters
·
06 Jun

Syndax exec buys $105.8K, director buys $91.1K in common stock

TIPRANKS
·
20 May